SCHEMBL10309338

SCHEMBL10309338

Cn1c(CCc2cn3ccccc3n2)nc2c3ccccc3ccc21

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 13/20 0.47
RAB9A P51151 5/20 0.41
PKM P14618 1/20 0.41
NPC1 O15118 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
DAPK3 O43293 1/20 0.39
ROCK2 O75116 1/20 0.39
PIM1 P11309 1/20 0.39
RPS6KB1 P23443 1/20 0.39
RPS6KA3 P51812 1/20 0.39
CSNK2A1 P68400 1/20 0.39
DYRK1A Q13627 1/20 0.39
PIM3 Q86V86 1/20 0.39
AURKB Q96GD4 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
KDM4E B2RXH2 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10309384 0.87 PDE10A (0.45) PDE10A
SCHEMBL10309448 0.86 PDE10A (0.66) PDE10ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL19846387 0.79 PDE10A (0.56) PDE10A
SCHEMBL10309363 0.77 PDE10A (0.75) PDE10A
SCHEMBL12068168 0.77 PDE10A (0.69) PDE10A
SCHEMBL18634556 0.76 PDE10A (0.39) PDE10ARAB9ANPC1SMN1; SMN2DAPK3
SCHEMBL15033341 0.74 PDE10A (0.46) PDE10AKDM4ELMNAMAPT
SCHEMBL10309462 0.74 PDE10A (0.74) PDE10A
SCHEMBL15033372 0.74 PDE10A (0.67) PDE10A
SCHEMBL10309450 0.73 PDE10A (0.61) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072759-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2018-03-15 US disclosed
US-9856274-B2 Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2018-01-02 US disclosed
US-20160102106-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2016-04-14 US disclosed
US-9249162-B2 Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2016-02-02 US disclosed
US-20140288062-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2014-09-25 US disclosed
US-8765760-B2 [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases SUNOVION PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-20120178748-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178748-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN PDE10A 2086/4885RAB9A 957/4885PKM 342/4885
US-20180072759-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN PDE10A 2086/4885RAB9A 957/4885PKM 342/4885
US-20140288062-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN PDE10A 2086/4885RAB9A 957/4885PKM 342/4885
US-20160102106-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN PDE10A 2086/4885RAB9A 957/4885PKM 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.